Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

This may be secondary to low concentrations of insulin-like growth factor (IGF)-I and GH hypersecretion.

The researchers tested the hypothesis that restoration of circulating IGF-I concentrations in young adults with T1DM might suppress GH secretion, GFR and urinary albumin excretion.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Subjects underwent overnight insulin infusion for euglycaemia, followed by determination of GFR and albumin excretion rate.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

As a double-blind IGF-1 LR3 study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

In the crossover set-up each of the participants took both IGF-1 LR3 and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Albuminuria, Analysis of Variance, Chemotherapy, Adjuvant, Creatinine, Depression, Chemical, Diabetes Mellitus, Type 1 and Glomerular Filtration Rate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of IGF-1 LR3.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2006 (Clinical endocrinology), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.